Synaffix Licenses Metal-Free Click Chemistry Technology to Illumina for Next-Generation DNA ...
Synaffix B.V., a Lonza company (SIX:LONN) focused on commercializing its clinical-stage bioconjugation platform technology for the ...
FierceBiotech18 小时
Gilead taps German biotech Tubulis for solid tumor ADC development deal worth up to $465M
Gilead isn’t the only Big Pharma to take an interest in Tubulis’ ADC tech. BMS paid the company $23 million upfront in April ...
BioSpace20 小时
Gilead Plots ADC Comeback with Potential $465M License Agreement
The deal with Tubulis will help Gilead regain its footing in the ADC space following the withdrawal of Trodelvy in bladder ...
pharmaphorum20 小时
Gilead looks beyond Trodelvy with Tubulis alliance
The deal with Tubulis gives Gilead access to the German biotech's ADC technology platform, designed to make ADCs more stable, ...
Gilead and Tubulis Enter Into Exclusive Option and License Agreement to Develop ADC ...
Gilead and Tubulis Enter Into Exclusive Option and License Agreement to Develop ADC Candidate for Select Solid Tumor Target ...
Gilead enters ADC option and license pact with Tubulis, sees dilution
Gilead (GILD) and Tubulis announced that they have entered into an exclusive option and license agreement to discover and develop an ...
Taiwan News6 天
CytomX Therapeutics to Present at the 36th Annual Piper Sandler Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Nov. 27, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced that Sean ...